- Home
- USEG vs CELU Comparison
USEG vs CELU Comparison
Compare USEG & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEG
- CELU
- Stock Information
- Founded
- USEG 1966
- CELU 2016
- Country
- USEG United States
- CELU United States
- Employees
- USEG N/A
- CELU N/A
- Industry
- USEG Oil & Gas Production
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- USEG Energy
- CELU Health Care
- Exchange
- USEG Nasdaq
- CELU Nasdaq
- Market Cap
- USEG 80.1M
- CELU 50.4M
- IPO Year
- USEG N/A
- CELU N/A
- Fundamental
- Price
- USEG $2.44
- CELU $1.99
- Analyst Decision
- USEG Strong Buy
- CELU
- Analyst Count
- USEG 2
- CELU 0
- Target Price
- USEG $2.75
- CELU N/A
- AVG Volume (30 Days)
- USEG 11.0M
- CELU 67.9K
- Earning Date
- USEG 03-25-2025
- CELU 12-06-2024
- Dividend Yield
- USEG N/A
- CELU N/A
- EPS Growth
- USEG N/A
- CELU N/A
- EPS
- USEG N/A
- CELU N/A
- Revenue
- USEG $22,257,000.00
- CELU $48,200,000.00
- Revenue This Year
- USEG N/A
- CELU N/A
- Revenue Next Year
- USEG $12.17
- CELU $233.89
- P/E Ratio
- USEG N/A
- CELU N/A
- Revenue Growth
- USEG N/A
- CELU 225.94
- 52 Week Low
- USEG $0.81
- CELU $1.30
- 52 Week High
- USEG $6.40
- CELU $7.97
- Technical
- Relative Strength Index (RSI)
- USEG 57.30
- CELU 38.25
- Support Level
- USEG $2.13
- CELU $1.97
- Resistance Level
- USEG $2.59
- CELU $2.72
- Average True Range (ATR)
- USEG 0.67
- CELU 0.21
- MACD
- USEG -0.04
- CELU -0.03
- Stochastic Oscillator
- USEG 14.25
- CELU 3.95
About USEG U.S. Energy Corp. (DE)
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business activities in South Texas and the Williston Basin in North Dakota. The company generates revenue from its interest in the sales of oil and natural gas production.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.